LIFE - aTyr Pharma, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.2700 |
| Open | 2.2700 |
| Bid | 0.0000 x 1300 |
| Ask | 0.0000 x 900 |
| Day's Range | 2.2239 - 2.3100 |
| 52 Week Range | 1.5550 - 4.2800 |
| Volume | |
| Avg. Volume | 652,787 |
| Market Cap | 123.242M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4000 |
| Earnings Date | Aug 14, 2023 - Aug 18, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.71 |
Fair Value
Related Research
GlobeNewswireaTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 2023 Jefferies Healthcare Conference, which is scheduled to take place June 7 – 9, 2023, in New York, NY. Details of the presentation appear below: C
- GlobeNewswire
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells to be featured in symposia presentation. Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy across multiple clinically relevant endpoints in pulmonary sarcoidosis patients. SAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
- Investing.com
Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: Sana Biotech, aTyr Pharma, and Theseus Pharma are set to share new data, and the FDA is set to review a Lexicon Pharma compound.
Simply Wall St.aTyr Pharma Independent Director Acquires 25% More Stock \
Potential aTyr Pharma, Inc. ( NASDAQ:LIFE ) shareholders may wish to note that the Independent Director, Paul Schimmel...
- GlobeNewswire
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference, which is scheduled to take place May 16 – 17, 2023, in New York, NY. Details of the presentation appear below: Conf
- Simply Wall St.
aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
ZacksAtyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023. Company to host multiple presentations for efzofitimod at the upcoming American Thoracic Society (ATS) 2023 International Conference. February follow-on common stock offering generated $48.1 million in net proceeds. Ended the first quarter 2023 with
InvestorPlace3 Stocks and Cryptos With the Highest Potential Returns
If you are only concerned about upside potential, looking into some stocks and cryptos with high returns is the way to go. The current environment is indeed very risky, with a recent rate hike and a recession on the horizon. Still, there are high-risk, high-return assets that can deliver multibagger gains if you’re lucky. However, I would note that chasing high upside potential comes with a lot of risks as you’d have to step foot into speculative territory. But the rewards can be just as rewardi
- InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear. Those same investors should also be well aware that they’ll be investing in cheaper stocks generally. Lower-priced shares have greater potential to multiply in value. That means investors looking for three-baggers will be looking at penny stocks which are, again, risky. Okay, you get it, to triple one’s capital in less than a year requires significant risk. However,
- GlobeNewswire
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancersSAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 14 – 19, 2023, in Orlando, FL. The abstract
- GlobeNewswire
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
Paper highlights efzofitimod as a first-in-class biologic with significant anti-inflammatory propertiesSAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a review article, titled, “Efzofitimod: a novel anti-inflammatory agent for sarcoidosis,” in the peer-reviewed journal Sarcoidosis, Vasculit
TipRanks2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon
Penny stocks are controversial, to say the least. When it comes to these under $5 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds. However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in t
- Simply Wall St.
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present f
- GlobeNewswire
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT.SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, and the Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoid
ZacksAtyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in 2023. February 2023 follow-on common stock offering of approximately $52.0 million in gross proceeds. Company to host conference call and webcast today, March 9th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or t
- GlobeNewswire
aTyr Pharma to Present at March Investor Conferences
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor conferences scheduled to take place in March 2023. Details of the presentations appear below: Conference: 35th Annual Roth ConferenceDate: Tuesday, March 14, 2023 Time: 10:00am PDTLocation: Dana Point, CAFor
- GlobeNewswire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results
Management to host conference call and webcast on March 9th at 5:00 pm EST / 2:00 pm PSTSAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management w
- GlobeNewswire
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided additional details regarding its plans to initiate a Phase 2 study of its lea
ZacksAtyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Simply Wall St.
With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest
To get a sense of who is truly in control of aTyr Pharma, Inc. ( NASDAQ:LIFE ), it is important to understand the...
- GlobeNewswire
aTyr Pharma Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share. The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions
- GlobeNewswire
aTyr Pharma Announces Commencement of Public Offering of Common Stock
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to an additional 15% of the shares sold in t
